• Report Adverse Event or Product Quality Complaint
  • US Site
  • Global Site
AstraZeneca Medical Information
  • Therapy Areas
    • All Therapeutic Areas
    • Cardiovascular
    • Immunology
    • Infection
    • Metabolic
    • Oncology
    • Renal
    • Respiratory
    • Rare Disease (Alexion)
  • Medications
  • Resources
    • Congress Library
    • Disease Education
    • Pipeline
    • Clinical Trials
    • Open innovation
    • Access 360
    • Affordability Programs
    • Sample Closet
    • Medical Education Grant
    • Rare Disease (Alexion)
  • Connect
    • Connect with Us
    • Find an MSL
    • Request an MSL
    • Submit an MIR
    • Give Feedback
User
  • Login to My AZmedical
  • Register for My AZmedical

Search Medical Information

American Academy of Neurology: (AAN 2025) 77th Annual Meeting

 April 5 - 9, 2025

  1. gMG
  2. Health Equity
  3. NMOSD

pdf

Assessment of hospitalizations in patients with generalized myasthenia gravis (gMG) before and during treatment with ravulizumab: results from a global registry

pdf

The phase 3 PREVAIL study assessing the efficacy and safety of subcutaneous gefurulimab in adults with generalized myasthenia gravis: trial in progress

pdf

Ravulizumab in patients with generalized myasthenia gravis from Japan: real-world outcomes

pdf

Long-term effectiveness and safety of eculizumab in patients with generalized myasthenia gravis real-world data from Japan

html

Characteristics of cohort with generalized myasthenia gravis in PREDICT study

html

Tracking daily impact of generalized myasthenia gravis using smartphone-based digital biomarkers: lessons learned from a 1-year study with ME&MGopen

pdf

The path to diagnosis and treatment among patients with generalized myasthenia gravis (gMG): health disparities experienced by racial and ethnic minorities from project ASPIRE (eliminAte diSparities and Promote equIty in Rare diseasE)

pdf

Evaluation of the indirect and nonmedical impacts of generalized myasthenia gravis on patients and caregivers

pdf

A phase 3, open-label, single-arm, multicenter study to evaluate ravulizumab administered intravenously in pediatric patients with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis

pdf

Change in concomitant immunosuppressive therapies for generalized myasthenia gravis in patients receiving complement C5 inhibitor therapies: a retrospective analysis of registry data

pdf

Effectiveness and safety of ravulizumab in generalized myasthenia gravis: updated analysis from a global registry

pdf

Outcomes for patients with gMG prescribed ravulizumab or efgartigimod treatment: A retrospective medical record analysis

pdf

The REthinking MeAsures of DivErsity (REMADE) study: developing new diversity measures to ensure fair representation in clinical trials

pdf

Patient preferences for treatment features in neuromyelitis optica spectrum disorder (NMOSD): results from a discrete choice experiment

pdf

Efficacy and safety of ravulizumab in adults with AQP4-Ab+ NMOSD: interim analysis from the ongoing phase 3 CHAMPION-NMOSD trial

html

ACT with NMOSD – a targeted, telehealth-delivered mental health intervention for NMOSD patients & caregivers

pdf

The total economic impact of anti-aquaporin-4 antibody-positive (AQP4-Ab+) neuromyelitis optica spectrum disorder (NMOSD) on patients and caregivers in the United States

pdf

NMO SPOTLIGHT Registry: real-world clinical outcomes with eculizumab and ravulizumab in anti-aquaporin-4 antibody-positive (AQP4-Ab+) neuromyelitis optica spectrum disorder (NMOSD)

pdf

Clinical characteristics associated with high baseline glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) levels in patients with anti-aquaporin-4 antibody-positive (AQP4-Ab+) neuromyelitis optica spectrum disorder (NMOSD) from the PREVENT and CHAMPION-NMOSD trials

pdf

Time to vaccination after rituximab (RTX) discontinuation in patients with anti–aquaporin–4 antibody–positive (AQP4-Ab+) neuromyelitis optica spectrum disorder (NMOSD): a post-hoc analysis of the CHAMPION-NMOSD trial

HTML

Clinical and radiological outcomes in people with Aquaporin-4 Antibody positive neuromyelitis optica spectrum disorder following ravulizumab treatment (AMAZE)

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Request a field medical follow-up

Welcome to AstraZeneca
Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am a payer or formulary decision-maker
I am neither (take me to AstraZeneca.com)
AstraZeneca Logo
Pharma Logo

This site is intended for healthcare professionals practicing in the US.

©2022 AstraZeneca. All rights reserved.

US-69609

Last Updated 11/22

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities

Survey Feedback

Your Privacy Choices

Privacy Notice

Legal Notice

Cookie Notice

US Site

Global Site

Report Adverse Event or Product Quality Complaint

Pharma Logo

Privacy NoticeLegal NoticeCookie Notice